Department of Neurology, University Hospital of Bonn, Bonn, Germany.
Neurology. 2011 Sep 13;77(11):1035-41. doi: 10.1212/WNL.0b013e31822e7ca0. Epub 2011 Aug 10.
To obtain quantitative data on the progression of the most common spinocerebellar ataxias (SCAs) and identify factors that influence their progression, we initiated the EUROSCA natural history study, a multicentric longitudinal cohort study of 526 patients with SCA1, SCA2, SCA3, or SCA6. We report the results of the 1- and 2-year follow-up visits.
As the primary outcome measure we used the Scale for the Assessment and Rating of Ataxia (SARA, 0-40), and as a secondary measure the Inventory of Non-Ataxia Symptoms (INAS, 0-16) count.
The annual increase of the SARA score was greatest in SCA1 (2.18 ± 0.17, mean ± SE) followed by SCA3 (1.61 ± 0.12) and SCA2 (1.40 ± 0.11). SARA progression in SCA6 was slowest and nonlinear (first year: 0.35 ± 0.34, second year: 1.44 ± 0.34). Analysis of the INAS count yielded similar results. Larger expanded repeats and earlier age at onset were associated with faster SARA progression in SCA1 and SCA2. In SCA1, repeat length of the expanded allele had a similar effect on INAS progression. In SCA3, SARA progression was influenced by the disease duration at inclusion, and INAS progression was faster in females.
Our study gives a comprehensive quantitative account of disease progression in SCA1, SCA2, SCA3, and SCA6 and identifies factors that specifically affect disease progression.
为获取有关最常见的脊髓小脑共济失调(SCA)进展的定量数据,并确定影响其进展的因素,我们启动了EUROSCA自然史研究,这是一项对526例SCA1、SCA2、SCA3或SCA6患者进行的多中心纵向队列研究。我们报告了1年和2年随访的结果。
作为主要结局指标,我们使用共济失调评估和评分量表(SARA,0 - 40),作为次要指标使用非共济失调症状量表(INAS,0 - 16)计数。
SARA评分的年增长在SCA1中最大(2.18 ± 0.17,均值 ± 标准误),其次是SCA3(1.61 ± 0.12)和SCA2(1.40 ± 0.11)。SCA6中SARA的进展最慢且呈非线性(第一年:0.35 ± 0.34,第二年:1.44 ± 0.34)。对INAS计数的分析得出了类似结果。更大的扩展重复序列和更早的发病年龄与SCA1和SCA2中更快的SARA进展相关。在SCA1中,扩展等位基因的重复长度对INAS进展有类似影响。在SCA3中,SARA进展受纳入时疾病持续时间的影响,并且女性的INAS进展更快。
我们的研究全面定量地描述了SCA1、SCA2、SCA3和SCA6的疾病进展,并确定了特异性影响疾病进展的因素。